We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.875 | 0.85 | 0.90 | 0.875 | 0.875 | 0.88 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.59 | 2.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/11/2018 13:14 | FWIW am now a holder here. The 95k trade yesterday was mine. Looked like a good double bottom and news due in next few weeks. | sicilian_kan | |
07/11/2018 12:58 | This is about to explode, quoted 23p to buy £10,000 worth. No stock left! | spmc | |
07/11/2018 12:48 | Good to see the price drifting up on relatively low volume. We are almost bound to see further strength ahead of the trial results at the end of the year IMHO. Onwards and upwards! Nobby | nobbygnome | |
04/11/2018 17:53 | Who cares ?I asked for your help as shafted by an Aim Director and you left me in lurch So much for helping Pi vs Aim corruption. | nico115 | |
04/11/2018 15:17 | Evgen Pharma present at our growth company seminar in Manchester on the 20th November which may be of interest to shareholders or potential investors. | sharesoc | |
01/11/2018 06:50 | I also bought stock here 200 shares I'm sure the twitter gang will get these to 20p at least ..last time 27p pre trial results !!Shop broker has a 113p from memory Strong buy Target 30p | nico115 | |
29/10/2018 09:49 | Just bought another 25k ahead of the trial results at the end of the year. Yes I know there are the fundraising shares to clear but not all of them will be finding their way on to the market. I am confident of a rise in price towards the end of the year and 13.5p seems a bargain price to me! | nobbygnome | |
24/10/2018 11:21 | Interesting research on Sulforaphane and Triple Negative Breast Cancer; Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells "The combination of sulforaphane and doxorubicin displayed a greater inhibitory effect on MDA-MB-231 xenografts growth as compared to either treatment alone." We should get the results of our study in this area using SFX-01 in the next couple of months. | pdt | |
18/10/2018 20:13 | I hate these placings, we won’t see any rise before the results now. These placings create an such a big overhang that drag down the price. With how low the volume is here there’s no way it will be cleared before the results :( | spmc | |
18/10/2018 13:08 | If they have a positive result from either phase II it strengthens their hand in negotiations. Personally I am happy with the small raise. | pdt | |
18/10/2018 10:57 | This is not really comparable with IMM but the size of the raise is a big concern... enough to cover 'a few months' after the pII trial is very short term planning and either suggests a lack of confidence in or by the bod, or they are banking on a serious collaboration deal that answers even the medium term funding needs.This doesn't fill me with confidence, continue to watch but I've removed my buy-in alert and will trade post the next RNS. | rathean | |
18/10/2018 09:34 | ;-) Just unable to check on the move Ps thanks for the info | sicilian_kan | |
18/10/2018 08:57 | s-k - lazy sod ;¬) Cancer is, stroke isn't. | supernumerary | |
18/10/2018 08:19 | Agreed. Not much of an insurance policy though in this case. Out of interest are the trials open label? Supernumerary - you make a good point. | sicilian_kan | |
18/10/2018 08:17 | Great Level to buy stockThis always runs up to trial results With the most important ones in December this will run up to 20pEspecially if the twitter gang bought in this placing !! | nico115 | |
18/10/2018 08:12 | Interims are due start of December - I don't know their cash position, but it's possible auditors are fretting about a going concern statement unless they have more cash in the kitty. I took the IMM fund raising as a big red card but I'm not sure the same applies here. | supernumerary | |
18/10/2018 07:42 | s_k Agreed. Not sure quite what to think. As an investor you wonder why they didnt wait until the anticipated good results are announced. However, as with IMM I guess it is an insurance policy. On the bright side for those looking to get in ahead of the trial results the price is now lower! | nobbygnome | |
18/10/2018 07:38 | Odd time and price for a placing. A watcher not a holder here. | sicilian_kan | |
16/10/2018 13:18 | Seems very quiet here especially since there should be a flurry of news over the next 3 or 4 months; Results expected from two Phase IIs and some pre-clinical news in particular Kings / Ischemic Stroke, Christies / Triple Negative Breast Cancer and Autism / Kings. Good chance of a licence deal from one of those two trials if they are positive. The risk/reward seems good to me for company with a market cap of £15m. There are of course negatives, we have seen what happens when small caps have disappointing trial results. And the cash must be tight now. On balance I have been adding. | pdt | |
08/10/2018 16:36 | >> btfd497 Your post deserves a reply from someone! Results from both the the SAH and breast cancer trial are due around the end of the year. Since we had positive interim results from the breast cancer trial and the lead investigator was very confident at the investor day recently, it would be extremely surprising if the final trial results weren't positive enough for the drug to proceed. The SAH trial is more difficult to predict but there is a high unmet need if it is successful. So IMHO the price is bound to rise ahead of the year end and I am beginning to put more money where my mouth is. If you are of a slightly nervous disposition, it would be certainly worth selling some ahead of the results if that rise does indeed happen. Of course just IMHO and you should DYOR..... Nobby | nobbygnome | |
08/10/2018 10:56 | I bought in at 21p back in early May and have been patiently waiting for the tides to turn as currently 25%down. I have two different options which I’m looking at. 1. Cut my losses and invest my £ elsewhere. 2. Double down to lower my average buy in. I don’t want to make any rash decisions so that’s why I’m asking the board... When are we likely to hear results etc. What sort of price could this go to if the results are good. Thanks :) | btfd497 | |
26/9/2018 08:04 | It's great to have some rational discussion on a thread for a change! It is a shame that people like francisgalton turn up to deliberately try to trash it. There is clear value here both short and medium term. | nobbygnome | |
26/9/2018 07:40 | Thanks nobby, timbo and pdt for the helpful information. So in summary, the core sulforaphane patents expire in 2028, however: - they have manufacturing and isolation / stabilisation patents to 2033 - they have data exclusivity (another company would have to replicate their preclinical and trial data and not rely on it) which is a significant hurdle to entry, for 10 years once approved, in Europe, and 7 years in orphan only conditions in the US. - there are analogues with patents to 2033 which appear to be better for oncology but which are not expected to be better for subarachnoid haemorrhage and other neurological indications. So not ideal, but there does on the face of it appear to be enough protection to ensure Evgen can generate value. | sicilian_kan | |
24/9/2018 10:48 | In addition to those patents there are Analogues granted running from 2013. Some of these have been tested and shown to have better properties in respect of cancer treatment than SFX-01. | pdt | |
24/9/2018 07:09 | See SFX-01 IP-schedule below. Patents generally expire 20 years after filing, but there are several forms of patent extension and marketing exclusivity extension which normally apply. For example, in the EU there is a 10 years exclusivity period (no cross referral to innovator’s regulatory data), plus one extra year if there is a new indication added since the original licence approval: In the US drugs with orphan indications are granted 7 year exclusivity (i.e. SFX-01 for SAH) From: | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions